Bristol-Myers Squibb Company Company Profile (NYSE:BMY)

About Bristol-Myers Squibb Company (NYSE:BMY)

Bristol-Myers Squibb Company logoBristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:BMY
  • CUSIP: 11012210
  • Web:
  • Market Cap: $92.52463 billion
  • Outstanding Shares: 1,639,926,000
Average Prices:
  • 50 Day Moving Avg: $55.95
  • 200 Day Moving Avg: $54.96
  • 52 Week Range: $46.01 - $60.45
  • Trailing P/E Ratio: 20.61
  • Foreward P/E Ratio: 18.32
  • P/E Growth: 2.25
Sales & Book Value:
  • Annual Revenue: $20.24 billion
  • Price / Sales: 4.57
  • Book Value: $8.96 per share
  • Price / Book: 6.30
  • Annual Dividend: $1.56
  • Dividend Yield: 2.8%
  • EBIDTA: $6.01 billion
  • Net Margins: 22.66%
  • Return on Equity: 32.33%
  • Return on Assets: 14.86%
  • Debt-to-Equity Ratio: 0.47%
  • Current Ratio: 1.59%
  • Quick Ratio: 1.45%
  • Average Volume: 7.27 million shs.
  • Beta: 1.17
  • Short Ratio: 2.45

Frequently Asked Questions for Bristol-Myers Squibb Company (NYSE:BMY)

What is Bristol-Myers Squibb Company's stock symbol?

Bristol-Myers Squibb Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How often does Bristol-Myers Squibb Company pay dividends? What is the dividend yield for Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company declared a quarterly dividend on Tuesday, June 13th. Shareholders of record on Friday, July 7th will be given a dividend of $0.39 per share on Tuesday, August 1st. This represents a $1.56 annualized dividend and a dividend yield of 2.76%. The ex-dividend date is Wednesday, July 5th. View Bristol-Myers Squibb Company's Dividend History.

How were Bristol-Myers Squibb Company's earnings last quarter?

Bristol-Myers Squibb Company (NYSE:BMY) announced its quarterly earnings results on Thursday, July, 27th. The company reported $0.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.01. The firm earned $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb Company had a net margin of 22.66% and a return on equity of 32.33%. The firm's revenue for the quarter was up 5.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.69 earnings per share. View Bristol-Myers Squibb Company's Earnings History.

When will Bristol-Myers Squibb Company make its next earnings announcement?

Bristol-Myers Squibb Company is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Bristol-Myers Squibb Company.

What guidance has Bristol-Myers Squibb Company issued on next quarter's earnings?

Bristol-Myers Squibb Company updated its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share (EPS) guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.94.

Where is Bristol-Myers Squibb Company's stock going? Where will Bristol-Myers Squibb Company's stock price be in 2017?

19 brokerages have issued 1-year price objectives for Bristol-Myers Squibb Company's shares. Their predictions range from $47.00 to $75.00. On average, they anticipate Bristol-Myers Squibb Company's stock price to reach $61.50 in the next year. View Analyst Ratings for Bristol-Myers Squibb Company.

What are analysts saying about Bristol-Myers Squibb Company stock?

Here are some recent quotes from research analysts about Bristol-Myers Squibb Company stock:

  • 1. Robert W. Baird analysts commented, "The broader opportunity for 2125, theoretically, is it could be used in many different tumor types and many different cancer indications." (4/25/2017)
  • 2. Jefferies Group LLC analysts commented, "Management seems to have scared investors out of the stock by saying they were "committed to" rather than confident on the Opdivo/ Yervoy combo. We see the guidance cut as a casualty of the new era of conservatism at BMY, though the market seems convinced MRK will get KN-021(G) approved by May anyway. We see a potential acquisition of BMY as increasingly likely as the stock moves towards our ex-lung valuation of $44." (1/27/2017)
  • 3. According to Zacks Investment Research, "Bristol-Myers key products – Opdivo, Orencia, Eliquis and Sprycel – should continue to fuel top-line growth of the company. The company raised its 2016 earnings guidance buoyed by strong trends across the business and posted an encouraging 2017 earnings outlook. Meanwhile, Bristol-Myers’ efforts to develop its pipeline are impressive. However, shares are under pressure with investors expressing disappointment over the company’s failed efforts to expand its key product Opdivo’s label to include the first-line treatment of lung cancer, which could give an edge to its competitors. The company announced that it will not seek an accelerated approval in the U.S. for Opdivo plus Yervoy, for first-line lung cancer. Shares of the company have underperformed that of the industry in the last one year. Moreover, estimates have come down ahead of the fourth-quarter results." (1/24/2017)
  • 4. BMO Capital Markets analysts commented, "Our recent survey with 31 oncologists across the U.S. supports our cautious views on BMY's IO franchise. 4Q16 should be O.K. as the IO franchise will likely beat because the Street is missing ex-US deferred revenue, but the focus remains on longer term outlook. 2017 EPS guidance could be lowered to account for NSCLC competitive dynamics and 3-5% Fx headwind. With ongoing setbacks in IO, we see increased execution risk. Given increased uncertainty about the potential of the IO franchise, we think a takeout/merger is less likely. We remain cautious." (1/23/2017)

Who are some of Bristol-Myers Squibb Company's key competitors?

Who are Bristol-Myers Squibb Company's key executives?

Bristol-Myers Squibb Company's management team includes the folowing people:

  • Giovanni Caforio M.D., Chairman of the Board, Chief Executive Officer
  • Charles A. Bancroft, Chief Financial Officer and Executive Vice President - Global Business Operations
  • Louis S. Schmukler, President - Global Manufacturing and Supply
  • Ann Powell Judge, Chief Human Resource Officer, Senior Vice President
  • Thomas J. Lynch Jr., M.D., Ph.D., Executive Vice President, Chief Scientific Officer
  • Sandra Leung, Executive Vice President, General Counsel
  • Murdo Gordon, Executive Vice President, Chief Commercial Officer
  • Paul von Autenried, Senior Vice President, Chief Information Officer
  • Anne Nielsen, Senior Vice President, Chief Compliance and Ethics Officer
  • Joseph C. Caldarella, Senior Vice President, Corporate Controller

Who owns Bristol-Myers Squibb Company stock?

Bristol-Myers Squibb Company's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.24%), BlackRock Inc. (6.06%), State Street Corp (4.13%), FMR LLC (2.23%), Capital World Investors (1.93%) and Dodge & Cox (1.80%). Company insiders that own Bristol-Myers Squibb Company stock include Autenried Paul Von, Charles A Bancroft, Giovanni Caforio, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Lewis B Campbell, Louis S Schmukler, Sandra Leung and Theodore R Samuels II. View Institutional Ownership Trends for Bristol-Myers Squibb Company.

Who sold Bristol-Myers Squibb Company stock? Who is selling Bristol-Myers Squibb Company stock?

Bristol-Myers Squibb Company's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Capital World Investors, Bank of Montreal Can, Thrivent Financial For Lutherans, Bessemer Group Inc., TIAA CREF Investment Management LLC, William Blair Investment Management LLC and Manning & Napier Advisors LLC. Company insiders that have sold Bristol-Myers Squibb Company stock in the last year include Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler and Sandra Leung. View Insider Buying and Selling for Bristol-Myers Squibb Company.

Who bought Bristol-Myers Squibb Company stock? Who is buying Bristol-Myers Squibb Company stock?

Bristol-Myers Squibb Company's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Franklin Resources Inc., Janus Henderson Group PLC, Arrowstreet Capital Limited Partnership, BlackRock Inc., Jennison Associates LLC, Harbour Capital Advisors LLC and Canada Pension Plan Investment Board. View Insider Buying and Selling for Bristol-Myers Squibb Company.

How do I buy Bristol-Myers Squibb Company stock?

Shares of Bristol-Myers Squibb Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bristol-Myers Squibb Company's stock price today?

One share of Bristol-Myers Squibb Company stock can currently be purchased for approximately $56.42.

MarketBeat Community Rating for Bristol-Myers Squibb Company (NYSE BMY)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  604 (Vote Outperform)
Underperform Votes:  574 (Vote Underperform)
Total Votes:  1,178
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Bristol-Myers Squibb Company (NYSE:BMY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 10 Buy Ratings
Consensus Rating:Hold (Score: 2.47)
Consensus Price Target: $61.50 (9.00% upside)

Analysts' Ratings History for Bristol-Myers Squibb Company (NYSE:BMY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017Credit Suisse GroupSet Price TargetHold$58.00MediumView Rating Details
8/14/2017Cowen and CompanySet Price TargetHold$65.00LowView Rating Details
8/9/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$63.00MediumView Rating Details
7/28/2017Leerink SwannLower Price TargetOutperform$66.00 -> $61.00LowView Rating Details
7/27/2017Piper Jaffray CompaniesSet Price TargetHold$60.00MediumView Rating Details
7/26/2017BMO Capital MarketsReiterated RatingUnderperform$51.00 -> $47.00LowView Rating Details
7/17/2017Deutsche Bank AGSet Price TargetHold$54.00 -> $55.00LowView Rating Details
7/12/2017Jefferies Group LLCReiterated RatingBuy$63.00MediumView Rating Details
6/26/2017William BlairReiterated RatingOutperformMediumView Rating Details
4/25/2017Robert W. BairdInitiated CoverageOutperformLowView Rating Details
2/22/2017ArgusReiterated RatingBuy$75.00N/AView Rating Details
2/9/2017GabelliReiterated RatingBuyN/AView Rating Details
1/24/2017Barclays PLCLower Price TargetEqual Weight$65.00 -> $58.00N/AView Rating Details
1/21/2017J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
1/8/2017Evercore ISIReiterated RatingHold$55.00N/AView Rating Details
11/8/2016Citigroup Inc.Reiterated RatingBuyN/AView Rating Details
10/28/2016Hilliard LyonsUpgradeNeutral -> Buy$69.00N/AView Rating Details
10/10/2016SunTrust Banks, Inc.Reiterated RatingHold$68.00 -> $62.00N/AView Rating Details
8/25/2016Morgan StanleyReiterated RatingNeutral -> HoldN/AView Rating Details
8/11/2016Berenberg BankDowngradeBuy -> Hold$80.00 -> $70.00N/AView Rating Details
8/11/2016Sanford C. BernsteinReiterated RatingMarket Perform$79.00 -> $65.00N/AView Rating Details
4/6/2016Societe GeneraleInitiated CoverageSell$48.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageUnderweight$57.00N/AView Rating Details
12/2/2015GuggenheimUpgradeNeutral -> Buy$82.00N/AView Rating Details
(Data available from 8/21/2015 forward)


Earnings History for Bristol-Myers Squibb Company (NYSE:BMY)
Earnings by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)
Earnings History by Quarter for Bristol-Myers Squibb Company (NYSE BMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$0.75N/AView Earnings Details
7/27/2017Q2 2017$0.73$0.74$5.09 billion$5.14 billionViewN/AView Earnings Details
4/27/2017Q1 2017$0.72$0.84$4.75 billion$4.93 billionViewN/AView Earnings Details
1/26/2017Q416$0.67$0.63$5.14 billion$5.24 billionViewN/AView Earnings Details
10/27/2016Q316$0.65$0.77$4.76 billion$4.83 billionViewListenView Earnings Details
7/28/2016Q216$0.67$0.69$4.60 billion$4.90 billionViewListenView Earnings Details
4/28/2016Q116$0.65$0.74$4.19 billion$4.39 billionViewListenView Earnings Details
1/28/2016Q415$0.28$0.38$4.07 billion$4.29 billionViewListenView Earnings Details
10/27/2015Q315$0.35$0.39$3.83 billion$4.07 billionViewListenView Earnings Details
7/23/2015Q215$0.36$0.53$3.68 billion$4.16 billionViewListenView Earnings Details
4/28/2015Q115$0.50$0.71$3.80 billion$4.04 billionViewN/AView Earnings Details
1/27/2015Q414$0.40$0.46$4.02 billion$4.26 billionViewN/AView Earnings Details
10/24/2014Q314$0.42$0.45$3.80 billion$3.92 billionViewListenView Earnings Details
7/24/2014Q214$0.44$0.48$3.85 billion$3.89 billionViewListenView Earnings Details
4/29/2014Q114$0.43$0.46$3.89 billion$3.81 billionViewListenView Earnings Details
1/24/2014Q413$0.43$0.53$4.30 billion$4.44 billionViewListenView Earnings Details
10/23/2013Q313$0.44$0.46$4.02 billion$4.07 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.45$0.44$4.07 billion$4.05 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.41$0.41$3.88 billion$3.83 billionViewListenView Earnings Details
1/24/2013Q4 2012$0.42$0.47$4.14 billion$4.19 billionViewListenView Earnings Details
10/24/2012$0.42$0.41ViewN/AView Earnings Details
7/25/2012$0.48$0.48ViewN/AView Earnings Details
4/26/2012$0.64$0.64ViewN/AView Earnings Details
1/26/2012$0.55$0.53ViewN/AView Earnings Details
10/27/2011$0.58$0.61ViewN/AView Earnings Details
7/28/2011$0.55$0.56ViewN/AView Earnings Details
4/28/2011$0.53$0.58ViewN/AView Earnings Details
1/27/2011$0.48$0.47ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Bristol-Myers Squibb Company (NYSE:BMY)
2017 EPS Consensus Estimate: $2.82
2018 EPS Consensus Estimate: $3.00
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.70$0.72$0.71
Q2 20173$0.70$0.76$0.73
Q3 20173$0.70$0.75$0.72
Q4 20173$0.62$0.68$0.65
Q1 20181$0.70$0.70$0.70
Q2 20181$0.72$0.72$0.72
Q3 20181$0.77$0.77$0.77
Q4 20181$0.81$0.81$0.81
(Data provided by Zacks Investment Research)


Current Dividend Information for Bristol-Myers Squibb Company (NYSE:BMY)
Most Recent Dividend:8/1/2017
Annual Dividend:$1.56
Dividend Yield:2.76%
Dividend Growth:2.80% (3 Year Average)
Payout Ratio:56.73% (Trailing 12 Months of Earnings)
52.53% (Based on This Year's Estimates)
50.65% (Based on Next Year's Estimates)
Track Record:7 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)

Dividend History by Quarter for Bristol-Myers Squibb Company (NYSE BMY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Bristol-Myers Squibb Company (NYSE:BMY)
Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 69.68%
Insider Trades by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)
Institutional Ownership by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)
Insider Trades by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/2/2017Theodore R Samuels IIDirectorBuy6,000$55.94$335,640.00View SEC Filing  
4/7/2017Lamberto AndreottiDirectorSell34,000$53.26$1,810,840.00View SEC Filing  
3/28/2017Lamberto AndreottiDirectorSell34,000$56.17$1,909,780.00View SEC Filing  
3/27/2017Lamberto AndreottiDirectorSell17,000$56.14$954,380.00View SEC Filing  
3/17/2017Louis S SchmuklerInsiderSell5,000$56.49$282,450.00View SEC Filing  
3/15/2017Joseph C CaldarellaSVPSell8,096$57.29$463,819.84View SEC Filing  
3/6/2017Sandra LeungEVPSell92,405$57.02$5,268,933.10View SEC Filing  
2/27/2017Theodore R Samuels IIDirectorBuy12,000$56.77$681,240.00View SEC Filing  
9/8/2016Lamberto AndreottiDirectorSell21,600$56.87$1,228,392.00View SEC Filing  
8/25/2016Lamberto AndreottiDirectorSell23,200$59.17$1,372,744.00View SEC Filing  
7/8/2016Lamberto AndreottiDirectorSell23,200$74.45$1,727,240.00View SEC Filing  
6/28/2016Lamberto AndreottiDirectorSell23,200$72.14$1,673,648.00View SEC Filing  
6/14/2016John E ElickerSVPSell11,820$72.69$859,195.80View SEC Filing  
5/20/2016Charles A BancroftCFOSell30,201$70.79$2,137,928.79View SEC Filing  
5/16/2016Joseph C CaldarellaSVPSell3,519$72.47$255,021.93View SEC Filing  
5/6/2016Sandra LeungEVPSell72,544$70.39$5,106,372.16View SEC Filing  
5/5/2016Lamberto AndreottiDirectorSell23,200$70.54$1,636,528.00View SEC Filing  
5/3/2016Giovanni CaforioCEOSell34,594$71.31$2,466,898.14View SEC Filing  
5/2/2016Autenried Paul VonSVPSell37,258$71.93$2,679,967.94View SEC Filing  
5/2/2016Lamberto AndreottiDirectorSell234,720$71.88$16,871,673.60View SEC Filing  
5/2/2016Louis S SchmuklerInsiderSell22,218$71.95$1,598,585.10View SEC Filing  
4/5/2016Lamberto AndreottiDirectorSell23,200$65.90$1,528,880.00View SEC Filing  
4/4/2016Lamberto AndreottiDirectorSell11,600$65.79$763,164.00View SEC Filing  
3/9/2016Lamberto AndreottiDirectorSell23,200$65.71$1,524,472.00View SEC Filing  
3/8/2016Lewis B CampbellDirectorSell2,500$66.00$165,000.00View SEC Filing  
3/4/2016Joseph C CaldarellaSVPSell12,962$64.64$837,863.68View SEC Filing  
2/17/2016Giovanni CaforioCEOSell12,040$63.58$765,503.20View SEC Filing  
2/17/2016Sandra LeungEVPSell10,152$63.57$645,362.64View SEC Filing  
2/12/2016Lamberto AndreottiDirectorSell23,200$59.61$1,382,952.00View SEC Filing  
1/5/2016Lamberto AndreottiDirectorSell23,200$67.56$1,567,392.00View SEC Filing  
1/4/2016Lamberto AndreottiDirectorSell11,600$66.93$776,388.00View SEC Filing  
12/15/2015Lamberto AndreottiDirectorSell23,200$69.03$1,601,496.00View SEC Filing  
11/20/2015Lamberto AndreottiDirectorSell23,200$67.39$1,563,448.00View SEC Filing  
10/6/2015Lamberto AndreottiDirectorSell23,200$60.86$1,411,952.00View SEC Filing  
9/3/2015Lamberto AndreottiDirectorSell23,200$59.40$1,378,080.00View SEC Filing  
6/4/2015Joseph C CaldarellaSVPSell16,972$65.71$1,115,230.12View SEC Filing  
3/16/2015Francis M CussEVPSell114,666$67.81$7,775,501.46View SEC Filing  
3/16/2015Louis S SchmuklerInsiderSell12,000$66.96$803,520.00View SEC Filing  
2/17/2015Sandra LeungGeneral CounselSell11,746$60.39$709,340.94View SEC Filing  
2/12/2015Samuel J MoedSVPSell3,880$59.26$229,928.80View SEC Filing  
2/6/2015Samuel J MoedSVPSell21,478$60.15$1,291,901.70View SEC Filing  
1/29/2015Lamberto AndreottiCEOSell90,246$61.14$5,517,640.44View SEC Filing  
1/29/2015Lewis B CampbellDirectorSell2,500$60.89$152,225.00View SEC Filing  
1/29/2015Louis S SchmuklerInsiderSell5,250$60.73$318,832.50View SEC Filing  
12/5/2014Lamberto AndreottiCEOSell75,000$60.31$4,523,250.00View SEC Filing  
10/24/2014Lamberto AndreottiCEOSell50,000$53.00$2,650,000.00View SEC Filing  
10/6/2014Lamberto AndreottiCEOSell50,000$50.99$2,549,500.00View SEC Filing  
9/16/2014Francis M CussEVPSell63,667$50.77$3,232,373.59View SEC Filing  
9/15/2014Giovanni CaforioCOOSell26,691$49.87$1,331,080.17View SEC Filing  
9/10/2014Joseph C CaldarellaSVPSell7,415$51.03$378,387.45View SEC Filing  
9/8/2014Lamberto AndreottiCEOSell50,000$51.05$2,552,500.00View SEC Filing  
8/19/2014Autenried Paul VonSVPSell20,000$49.89$997,800.00View SEC Filing  
7/29/2014Charles A BancroftCFOSell67,621$51.06$3,452,728.26View SEC Filing  
7/28/2014Samuel J MoedSVPSell25,752$49.32$1,270,088.64View SEC Filing  
3/13/2014Joseph CaldarellaSVPSell9,137$55.20$504,362.40View SEC Filing  
3/10/2014Lamberto AndreottiCEOSell100,000$55.52$5,552,000.00View SEC Filing  
3/10/2014Louis SchmuklerInsiderSell8,799$55.81$491,072.19View SEC Filing  
3/5/2014James CorneliusDirectorSell100,000$55.82$5,582,000.00View SEC Filing  
2/28/2014Louis SchmuklerInsiderSell6,088$54.49$331,735.12View SEC Filing  
2/24/2014Giovanni CaforioEVPSell41,563$54.44$2,262,689.72View SEC Filing  
2/19/2014John ElickerSVPSell9,534$54.22$516,933.48View SEC Filing  
2/18/2014Francis CussEVPSell29,800$54.61$1,627,378.00View SEC Filing  
2/14/2014Charles BancroftCFOSell52,963$54.35$2,878,539.05View SEC Filing  
2/14/2014Sandra LeungGeneral CounselSell10,490$54.28$569,397.20View SEC Filing  
2/11/2014Lamberto AndreottiCEOSell86,075$52.66$4,532,709.50View SEC Filing  
2/6/2014Joseph CaldarellaSVPSell35,471$48.90$1,734,531.90View SEC Filing  
2/5/2014Lewis CampbellDirectorSell2,500$48.28$120,700.00View SEC Filing  
2/4/2014James CorneliusDirectorSell100,000$48.90$4,890,000.00View SEC Filing  
7/29/2013James M CorneliusDirectorSell5,000$43.81$219,050.00View SEC Filing  
6/10/2013Autenried Paul VonSVPSell25,000$47.24$1,181,000.00View SEC Filing  
6/6/2013Joseph C CaldarellaSVPSell26,275$46.53$1,222,575.75View SEC Filing  
6/5/2013John E ElickerSVPSell25,997$46.33$1,204,441.01View SEC Filing  
6/4/2013Lamberto AndreottiCEOSell100,000$47.74$4,774,000.00View SEC Filing  
6/4/2013Samuel J MoedSVPSell58,898$47.38$2,790,587.24View SEC Filing  
6/3/2013Elliot SigalEVPSell83,647$48.18$4,030,112.46View SEC Filing  
5/31/2013Beatrice J CazalaEVPSell91,282$47.00$4,290,254.00View SEC Filing  
5/31/2013Giovanni CaforioInsiderSell10,538$47.06$495,918.28View SEC Filing  
5/30/2013Beatrice J CazalaEVPSell22,000$47.00$1,034,000.00View SEC Filing  
5/28/2013Charles A BancroftCFOSell25,000$48.68$1,217,000.00View SEC Filing  
5/28/2013James M CorneliusDirectorSell100,000$47.61$4,761,000.00View SEC Filing  
5/23/2013Beatrice J CazalaEVPSell96,000$46.99$4,511,040.00View SEC Filing  
5/23/2013Giovanni CaforioInsiderSell26,647$46.29$1,233,489.63View SEC Filing  
5/17/2013James M CorneliusDirectorSell225,996$42.99$9,715,568.04View SEC Filing  
5/8/2013James M CorneliusDirectorSell20,000$39.85$797,000.00View SEC Filing  
5/2/2013James M CorneliusDirectorSell20,000$39.76$795,200.00View SEC Filing  
4/11/2013James M CorneliusDirectorSell20,000$41.15$823,000.00View SEC Filing  
3/13/2013James M CorneliusDirectorSell20,000$38.18$763,600.00View SEC Filing  
3/13/2013John E ElickerSVPSell3,409$38.51$131,280.59View SEC Filing  
2/27/2013Giovanni CaforioInsiderSell12,150$37.08$450,522.00View SEC Filing  
2/26/2013James M CorneliusDirectorSell20,000$36.58$731,600.00View SEC Filing  
1/17/2013James M CorneliusDirectorSell20,000$34.33$686,600.00View SEC Filing  
12/28/2012James M CorneliusDirectorSell20,000$32.06$641,200.00View SEC Filing  
10/3/2012James M CorneliusDirectorSell20,000$33.71$674,200.00View SEC Filing  
8/10/2012James M CorneliusDirectorSell10,000$31.81$318,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Bristol-Myers Squibb Company (NYSE:BMY)
Latest Headlines for Bristol-Myers Squibb Company (NYSE:BMY)
DateHeadline logoBristol-Myers Squibb Sees Unusually High Options Volume (BMY) - August 20 at 1:24 AM logoBristol-Myers Squibb (BMY), Pfizer (PFE) to Highlight Commitment to Reducing Risk of Stroke Caused by NVAF and Treating DVT/PE at ESC Congress - August 19 at 4:11 PM logoBristol-Myers Squibb (BMY), Pfizer (PFE) to Highlight Commitment to ... - - August 18 at 9:46 PM logoBristol-Myers Squibb and Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by Non-Valvular Atrial Fibrillation (NVAF) and Treating Deep Vein Thrombosis ... - August 18 at 4:46 PM logoPharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo - August 18 at 4:46 PM logoAnalysts’ Recommendations for Bristol-Myers Squibb in August 2017 - August 18 at 4:46 PM logoOpdivo Could Drive Bristol-Myers Squibb’s Revenue Growth in 2017 - August 18 at 4:46 PM logoFY2018 EPS Estimates for Bristol-Myers Squibb Company (BMY) Reduced by William Blair - August 18 at 12:52 PM logoSunTrust Banks Research Analysts Lift Earnings Estimates for Bristol-Myers Squibb Company (BMY) - August 18 at 7:02 AM logoBristol-Myers Squibb Company (BMY) Raised to Strong-Buy at Vetr Inc. - August 18 at 12:34 AM logoWilliam Blair Comments on Bristol-Myers Squibb Company's FY2019 Earnings (BMY) - August 17 at 3:38 PM logoBristol-Myers Squibb Combination Treatment Not At The End Of The Crossroad - August 16 at 10:14 PM logoStocks to Watch: Target, Apple, Amazon, Urban Outfitters, Bristol-Myers - August 16 at 10:13 PM logoBristol-Myers Squibb Stock Falls as Kidney Cancer Drug Fails - August 16 at 10:13 PM logoBiotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis - - August 16 at 5:13 PM logoBristol-Myers Squibb Stock Falls as Kidney Cancer Drug Fails - - August 16 at 5:13 PM logoBristol-Myers Squibb shares slip as kidney cancer drug trial falls short of goal - MarketWatch - August 16 at 5:13 PM logo3 Big Stock Charts for Tuesday: Bristol-Myers Squibb Co (BMY), United Parcel Service, Inc. (UPS) and Intuit Inc. (INTU) - - August 16 at 5:13 PM logoBristol-Myers Opdivo Fails Kidney Cancer Trial CheckMate-214 - August 16 at 5:13 PM logoCramer: Investors Can't Get Enough of Bristol-Myers Despite Latest Drug Setback - August 16 at 5:13 PM logoMarket Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive' - August 16 at 5:13 PM logo[$$] Bristol-Myers Can Overcome Market's Pessimism - August 16 at 5:13 PM logoCredit Suisse Group Analysts Give Bristol-Myers Squibb Company (BMY) a $58.00 Price Target - August 16 at 8:02 AM logoBristol-Myers Squibb (BMY) Says CheckMate -214 Combination Study Met Co-primary Endpoint of ORR but PFS Didn't Reach Statistical Significance - August 16 at 3:33 AM logoBRIEF-Bristol-Myers Squibb announces topline results - August 15 at 5:30 PM logoBristol-Myers Squibb: HIV Franchise Was Never A Big Part Of The Game Plan - August 15 at 5:30 PM logoBristol-Myers Squibb Announces Topline Results from CheckMate -214, a Phase 3 Study of Opdivo in Combination with Yervoy in Intermediate and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma - August 15 at 5:29 PM logoBristol-Myers Squibb shares slip as kidney cancer drug trial falls short of goal - August 15 at 5:29 PM logoBristol-Myers Squibb Company (BMY) Given a $65.00 Price Target by Cowen and Company Analysts - August 14 at 6:38 PM logoBristol-Myers Squibb Company (NYSE:BMY) Upgraded to "Hold" by BidaskClub - August 12 at 3:18 PM logoETFs with exposure to Bristol-Myers Squibb Co. : August 11, 2017 - August 11 at 10:04 PM logoBristol-Myers Squibb Company (NYSE:BMY) Given Average Rating of "Hold" by Brokerages - August 11 at 6:48 PM logoSee what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. - August 11 at 5:03 PM logoPfizer’s Valuation after 2Q17 Earnings - August 11 at 5:03 PM logoIHS Markit Score Update: Drop in demand for ETFs holding Bristol-Myers Squibb Co is a negative sign for its shares - August 11 at 3:58 AM logoIHS Markit Score Update: Decline in perceived credit worthiness is a negative sign for Bristol-Myers Squibb Co shares - August 10 at 10:56 PM logo$5.15 Billion in Sales Expected for Bristol-Myers Squibb Company (NYSE:BMY) This Quarter - August 10 at 12:47 PM logoVetr Inc. Downgrades Bristol-Myers Squibb Company (NYSE:BMY) to Buy - August 10 at 12:58 AM logoBristol-Myers Squibb's (NYSE:BMY) Buy Rating Reiterated at Goldman Sachs Group, Inc. (The) - August 10 at 12:22 AM logoCelldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up - August 9 at 4:50 PM logoBristol-Myers Squibb (BMY) Could Be Worth $59-$75 In Takeout W/O CM-227 - Goldman - August 9 at 2:29 AM logoBristol-Myers Squibb Co (NYSE:BMY) Expected to Announce Earnings of $0.75 Per Share - August 8 at 8:20 PM logoBristol-Myers Squibb (BMY) Could Be Worth $59-$75 In Takeout W/O CM-227 - Goldman - - August 8 at 4:25 PM logoRetail names soar on earnings - August 8 at 4:25 PM logoBristol-Myers - Adding To The Pipeline With IFM - August 7 at 5:11 PM logoQ2 Earnings Fail to Impress Pharma ETF - August 7 at 5:11 PM logoBristol-Myers Squibb: A Combined Value And Growth Story - Seeking Alpha - August 7 at 2:09 AM logoStock Traders Buy High Volume of Put Options on Bristol-Myers Squibb (BMY) - August 6 at 7:00 AM logo[$$] Atlas Venture Scores Hat Trick of Early-Stage Biotech Exits - August 4 at 9:56 PM logoBristol-Myers Squibb Company (BMY) Director Acquires $335,640.00 in Stock - August 3 at 8:20 PM



Bristol-Myers Squibb Company (BMY) Chart for Monday, August, 21, 2017

This page was last updated on 8/21/2017 by Staff